Also known as: GLP-1 agonists, Incretin agonists, Weight loss medications
Depending on your genotype, these 3 medications split into up to 2 groups, from take-as-directed through to worth avoiding. Gene2Rx Pro reads GIPR and GLP1R from your own report and tells you which is which.
GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) are the dominant new drug class for weight management and type 2 diabetes. They all work the same way: activating incretin receptors slows gastric emptying, increases satiety, and improves insulin response. Two SNPs are robustly associated with how people respond, though they account for only a small share of the overall variation, most of which is non-genetic. GLP1R rs10305420 affects every drug in the class. GIPR rs1800437 only matters for drugs that also activate GIP, which is tirzepatide and retatrutide.[1]
For a deeper walk-through of the GLP1R variant associated with weight loss, and the GIPR variant associated with nausea and vomiting risk on tirzepatide, see our GLP-1 genetics guide.
Each link goes to the drug's full pharmacogenetics page with CPIC and FDA phenotype recommendations.
Combined products and brand names for the medications above. Each links to a pharmacogenetic breakdown.
This page covers the pharmacogenetics of weight management (glp-1 agonists) in general. A Gene2Rx report tells you how your personal genotype interacts with every drug on this page.
Get your report Look up a medicationInformational only, not medical advice. Pharmacogenetic guidelines describe population-level patterns that inform prescribing decisions. Never start, stop, or change a medication without talking to your prescribing clinician.